Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 813,937 | 767,427 | 407,468 | 393,098 | 309,504 |
| Depreciation Amortization | 2,636,991 | 1,316,759 | 5,369,571 | 4,028,873 | 3,180,321 |
| Accounts receivable | -14,495 | -240,359 | -320,399 | -634,055 | -501,623 |
| Accounts payable and accrued liabilities | -247,558 | -215,323 | -275,374 | -360,594 | -385,736 |
| Other Working Capital | 156,247 | -819,163 | 870,982 | 378,672 | 215,360 |
| Other Operating Activity | 339,782 | 547,165 | 109,470 | 649,704 | 354,283 |
| Operating Cash Flow | $3,684,903 | $1,356,507 | $6,161,718 | $4,455,698 | $3,172,109 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -112,274 | -214,914 | -1,053,437 | -824,210 | -511,630 |
| Net Acquisitions | 295,160 | N/A | 4,201,235 | 3,412,703 | 3,449,891 |
| Purchase Of Investment | -58,459 | -32,708 | -69,469 | -67,408 | -36,698 |
| Sale Of Investment | 476,110 | 413,264 | 454,498 | 439,714 | 377,413 |
| Purchase Sale Intangibles | -285,882 | -161,281 | -833,778 | -597,834 | -198,592 |
| Other Investing Activity | -335,232 | -159,486 | -845,332 | -606,758 | -206,126 |
| Investing Cash Flow | $265,306 | $6,157 | $2,687,495 | $2,354,041 | $3,072,850 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 11,087,440 | N/A | 4,564,948 | 4,564,948 | 4,614,567 |
| Debt Repayment | -11,896,910 | -92,805 | -6,449,725 | -5,732,971 | -5,795,007 |
| Common Stock Repurchased | -20,069 | -19,828 | -34,380 | -34,270 | -34,633 |
| Dividend Paid | -1,332,488 | -1,237,969 | -2,599,754 | -2,523,174 | -1,309,542 |
| Other Financing Activity | -1,769,147 | -442,113 | -4,729,049 | -4,198,327 | -5,023,916 |
| Financing Cash Flow | $-3,931,174 | $-1,792,714 | $-9,247,960 | $-7,923,794 | $-7,548,531 |
| Exchange Rate Effect | -80,558 | -14,741 | -200,247 | -122,820 | -177,035 |
| Beginning Cash Position | 5,993,572 | 5,929,810 | 6,465,042 | 6,459,255 | 6,529,465 |
| End Cash Position | 5,932,049 | 5,485,019 | 5,866,049 | 5,228,167 | 5,054,708 |
| Net Cash Flow | $-61,523 | $-444,791 | $-598,993 | $-1,231,088 | $-1,474,757 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,684,903 | 1,356,507 | 6,161,718 | 4,455,698 | 3,172,109 |
| Capital Expenditure | -474,503 | -215,156 | -1,169,154 | -826,574 | -512,272 |
| Free Cash Flow | 3,210,400 | 1,141,352 | 4,992,564 | 3,629,124 | 2,659,837 |